GlassScriptPhysician profile
Dalton Stephen Menke
NPI 1871118174
$10,707.39
in general payments reported to CMS, 2019-2025
30 companies · $5,820 in 2025
The $5,820 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $477 · 2023: $1,721 · 2024: $2,689 · 2025: $5,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,892 · Education: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,891.53 |
| Education | $338.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,566.39 | 2022-2025 | |
| Ucb, INC. | $1,099.08 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $921.39 | 2023-2025 | Blu-U, Odomzo, Ilumya |
| Genzyme Corporation | $829.43 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $709.06 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $654.56 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $571.54 | 2023-2025 | Otezla, Otezla |
| Organon LLC | $480.45 | 2024-2025 | Vtama, Hadlima, Nexplanon |
| Novartis Pharmaceuticals Corporation | $442.04 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $286.11 | 2023-2025 | Sotyktu |
| Pfizer INC. | $264.88 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $249.05 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $236.37 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $223.65 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $198.90 | 2023-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $150.30 | 2022 | |
| Mayne Pharma Commercial LLC | $128.66 | 2023-2025 | |
| Leo Pharma INC. | $103.11 | 2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.03 | 2023-2025 | Spevigo, Cyltezo |
| Ani Pharmaceuticals, INC. | $93.02 | 2025 | Purified Cortrophin Gel |
| Mimedx Group, INC. | $69.41 | 2024 | |
| Almirall LLC | $61.19 | 2023-2024 | Klisyri |
| Incyte Corporation | $48.53 | 2025 | Opzelura |
| Mallinckrodt Hospital Products INC. | $29.39 | 2025 | Acthar |
| Merck Sharp & Dohme LLC | $24.95 | 2025 | Keytruda |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.63 | 2024 | Cabtreo |
| Biofrontera INC. | $18.81 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lnhc, INC | $15.92 | 2025 | Zelsuvmi |
| Springworks Therapeutics, INC. | $13.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalton Menke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.